Peer-Reviewed Journal Details
Mandatory Fields
Wawrzynska, M;Kraskiewicz, H;Paprocka, M;Krawczenko, A;Bielawska-Pohl, A;Bialy, D;Roleder, T;Wojakowski, W;O'Connor, IB;Duda, M;Michal, R;Wasyluk, L;Plesch, G;Podbielska, H;Kopaczynska, M;Wall, JG
2020
January
Journal Of Biomedical Materials Research Part B-Applied Biomaterials
Functionalization with a VEGFR2-binding antibody fragment leads to enhanced endothelialization of a cardiovascular stent in vitro and in vivo
Published
Optional Fields
SIROLIMUS-ELUTING STENTS DUAL THERAPY STENT RE-ENDOTHELIALIZATION PROGENITOR CELLS CORONARY STENT SURFACE IMMOBILIZATION TECHNOLOGY RESTENOSIS CAPTURE
108
213
224
Rapid endothelialization of cardiovascular stents is critical to prevent major clinical complications such as restenosis. Reconstruction of the native endothelium on the stent surface can be achieved by the capture of endothelial progenitor cells (EPCs) or neighboring endothelial cells (ECs) in vivo. In this study, stainless steel cardiovascular stents were functionalized with recombinant scFv antibody fragments specific for vascular endothelial growth factor receptor-2 (VEGFR2) that is expressed on EPCs and ECs. Anti-VEGFR2 scFvs were expressed in glycosylated form in Escherichia coli and covalently attached to amine-functionalized, titania-coated steel disks and stents. ScFv-coated surfaces exhibited no detectable cytotoxicity to human ECs or erythrocytes in vitro and bound 15 times more VEGFR2-positive human umbilical vein ECs than controls after as little as 3 min. Porcine coronary arteries were successfully stented with scFv-coated stents with no adverse clinical events after 30 days. Endovascular imaging and histology revealed coverage of the anti-VEGFR2 scFv-coated stent with a cell layer after 5 days and the presence of a neointima layer with a minimum thickness of 80 mu m after 30 days. Biofunctionalization of cardiovascular stents with endothelial cell-capturing antibody fragments in this manner offers promise in accelerating stent endothelialization in vivo. (c) 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 108B:213-224, 2020.
1552-4973
10.1002/jbm.b.34380
Grant Details
Publication Themes